# Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer

> **NCT06830239** · PHASE2 · RECRUITING · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 10 (estimated)

## Conditions studied

- Colon Cancer Stage III

## Interventions

- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT06830239
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-03
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06830239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06830239, "Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06830239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*